Cover Image

PCSK9 inhibition and broad health outcomes: A Mendelian randomization phenome‑wide association study

Saved in:

Bibliographic Details
Main Authors:	Kai Zhang (Author), Qin Bian (Author)
Format:	Book
Published:	Elsevier, 2024-05-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Proteome-wide mendelian randomization investigates potential associations in heart failure and its etiology: emphasis on PCSK9
by: Lichao Lin, et al.
Published: (2024)

Genetic variations in HMGCR and PCSK9 and kidney function: a Mendelian randomization study
by: Sehoon Park, et al.
Published: (2023)

Phenomics
by: Marcos Egea-Cortines
Published: (2018)

Phenome-Wide Association Study With Focus on Oral Health Disparities and Individuals Who Did Not Have Cancer
by: Mariana Bezamat, et al.
Published: (2021)

A phenome-wide approach to identify causal risk factors for deep vein thrombosis
by: Andrei-Emil Constantinescu, et al.
Published: (2023)

Inclisiran-Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
by: Łukasz Wołowiec, et al.
Published: (2023)

Juvenile idiopathic arthritis polygenic risk scores are associated with cardiovascular phenotypes in early adulthood: a phenome-wide association study
by: Sarah L. N. Clarke, et al.
Published: (2022)

Plant Phenotyping and Phenomics for Plant Breeding
by: Gustavo A. Lobos
Published: (2018)

PCSK9 INHIBITORS IN PERIPHERAL ARTERY DISEASE: REVIEW OF EFFICACY, SAFETY, AND OUTCOMES
by: Moiud Mohyeldin
Published: (2024)

Rush to Judgement: Imaginary Worlds and Cost-Outcomes Claims for PCSK9 Inhibitors
by: Paul C Langley, Dr
Published: (2017)

Causal gene identification using mitochondria-associated genome-wide mendelian randomization in atrial fibrillation
by: Ying Chen, et al.
Published: (2024)

A Comprehensive Review of PCSK9 Inhibitors
by: Caroline Coppinger BS, et al.
Published: (2022)

The Anti-Thrombotic Effects of PCSK9 Inhibitors
by: Martin Jozef Péč, et al.
Published: (2023)

Therapeutic targets for lung cancer: genome-wide Mendelian randomization and colocalization analyses
by: Yi Luan, et al.
Published: (2024)

Systematic druggable genome‐wide Mendelian randomization identifies therapeutic targets for sarcopenia
by: Kang‐Fu Yin, et al.
Published: (2024)

Why does human phenomics matter today?
by: Vasa Curcin
Published: (2020)

Safety and Tolerability of PCSK9 Inhibitors: Current Insights
by: Kosmas CE, et al.
Published: (2020)

Analysis of The Use of PCSK9 Inhibitors in Clinical Practice
by: S. Yu. Volkova, et al.
Published: (2023)

PCSK9 Inhibitor Therapy as an Alternative for Statin Intolerance
by: K. O. Shnaider, et al.
Published: (2023)

Association between Plasma PCSK9 levels and Presence of Coronary Artery Calcium
by: Tahir Mahmood, et al.
Published: (2020)

Pathway networks generated from human disease phenome
by: Ann G. Cirincione, et al.
Published: (2018)

Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond
by: Maya Safarova, et al.
Published: (2024)

Sex difference in circulating PCSK9 and its clinical implications
by: Fang Jia, et al.
Published: (2022)

Association between PCSK9 inhibitors and acute kidney injury: a pharmacovigilance study
by: Hailing Liu
Published: (2024)

PCSK9 Expression in Epicardial Adipose Tissue: Molecular Association with Local Tissue Inflammation
by: Elena Dozio, et al.
Published: (2020)

Therapeutic targets for muscle weakness in older adults: proteome-wide Mendelian randomization and colocalization analyses
by: Shuai-Kang Wang, et al.
Published: (2024)

PCSK-9 inhibitors: a new direction for the future treatment of ischemic stroke
by: Lin Zhou, et al.
Published: (2024)

The Role of PCSK9 Inhibitors in the Improvement of Outcomes in Patients after Acute Coronary Syndrome: Results of ODYSSEY OUTCOMES Trial
by: Yu. A. Karpov
Published: (2019)

Chimeric Peptide Engineered Nanomedicine for Synergistic Suppression of Tumor Growth and Therapy-Induced Hyperlipidemia by mTOR and PCSK9 Inhibition
by: Hua Cai, et al.
Published: (2023)

Impact of PCSK9 Inhibition on Proinflammatory Cytokines and Matrix Metalloproteinases Release in Patients with Mixed Hyperlipidemia and Vulnerable Atherosclerotic Plaque
by: Marcin Basiak, et al.
Published: (2022)

The wind of change - PCSK9 inhibitors in hypolipidemic treatment. The Polish perspective
by: Natalia Ilnicka, et al.
Published: (2023)

PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD)
by: Saeideh Sobati, et al.
Published: (2020)

PCSK9 Monoclonal Antibodies for the Primary and Secondary Prevention of Cardiovascular Disease
by: article Editorial
Published: (2023)

The E670G SNP in the <it>PCSK9 </it>gene is associated with polygenic hypercholesterolemia in men but not in women
by: Beil Frank U, et al.
Published: (2006)

Acne and risk of mental disorders: A two-sample Mendelian randomization study based on large genome-wide association data
by: Lin Liu, et al.
Published: (2023)

Innovate therapeutic targets for autoimmune diseases: insights from proteome-wide mendelian randomization and Bayesian colocalization
by: Qiubai Jin, et al.
Published: (2024)

Association study of PCSK9 SNPs (rs505151 & rs562556) and their haplotypes with CVDs in Indian population
by: Kiran Devi, et al.
Published: (2023)

Association of antihypertensive drugs with COVID-19 outcomes: a drug-target Mendelian randomization study
by: Kun Zhang, et al.
Published: (2023)

COMPARISON OF QUALITY OF LIFE IN PATIENTS WITH PCSK9 INHIBITORS VS. STATIN INTOLERANCE
by: Mohsin Haseeb, et al.
Published: (2023)

Unusual Responses to PCSK9 Inhibitors in a Real-world Clinical Cohort
by: Bruce A. Warden, et al.
Published: (2020)